 |
|
|
|
|
|
 Title: |
US5929034:
Use of α-conotoxin MII to treat disorders resulting from nicotine-stimulated dopamine release
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
McIntosh, J. Michael; Salt Lake City, UT
Kulak, Jennifer M.; Salt Lake City, UT
Yoshikami, Doju; Salt Lake City, UT
Olivera, Baldomero M.; Salt Lake City, UT
|
| Assignee: |
University of Utah Research Foundation, Salt Lake City, UT
other patents from UNIVERSITY OF UTAH RESEARCH FOUNDATION (600050) (approx. 286)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
1999-07-27
/ 1998-03-23
|
| Application Number: |
US1998000045926
|
| IPC Code: |
Advanced:
A61K 38/17;
Core:
more...
IPC-7:
A61K 38/00;
|
| ECLA Code: |
A61K38/17;
|
| U.S. Class: |
Current:
514/013;
Original:
514/013;
|
| Field of Search: |
514/013
|
| Government Interest: |
This invention was made with Government support under Grant Nos. MH 53631 and GM 48677, awarded by the National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.
|
| Priority Number: |
|
| Abstract: |
Neuronal nicotinic acetylcholine receptors (nAChRs) are believed to mediate nicotine addiction. In addition, stimulation of nAChRs modulates release of neurotransmitters including dopamine, norepinephrine and serotonin. Thus, pharmacological manipulation of nicotinic receptors has implications for a wide variety of disorders including psychotic, mood, movement and cognitive. For most nAChRs, there are no subtype selective ligands. However, α-conotoxin MII, a small peptide from the carnivorous marine snail Conus magus, was recently isolated. This peptide has been shown to be a specific antagonist for α3β2 nicotinic receptors. The peptide potently blocks part, but not all, of nicotine-stimulated dopamine release from rat brain striatal synaptosomes. In contrast it has no effect on potassium stimulated dopamine release. Other α-conotoxins specifically target distinct neuronal nAChR subtypes. α-Conotoxins thus represent new lead compounds for CNS disorders.
|
| Attorney, Agent or Firm: |
Rothwell, Figg, Ernst & Kurz, P.C. ;
|
| Primary / Asst. Examiners: |
Cook, Rebecca;
|
| INPADOC Legal Status: |
None
Family Legal Status Report
|
|
Nominate this for the Gallery...
